Overview
The KLOW blend (KPV + GHK-Cu + BPC-157 + TB-500) extends the GLOW formulation with the addition of KPV (the C-terminal tripeptide of α-MSH), producing a four-peptide research preparation. Research interest in this blend focuses on the combination of KPV’s anti-inflammatory pathway research activity with the matrix remodeling and cellular migration profiles of the three GLOW components (see individual compound entries for foundational references).
History
The KLOW blend emerged as an extension of GLOW research protocols, incorporating KPV as a fourth component to add anti-inflammatory pathway research coverage. Each individual component has independent preclinical literature; the blend configuration reflects research interest in combining four peptides with overlapping activity domains (Brzoska et al., 2008; Pickart & Margolina, 2018; Sikiric et al., 2020; Goldstein et al., 2005).
Structure & Molecular Data
| CAS Number | N/A (synthetic peptide blend) |
| Molecular Formula | Blend: KPV + GHK-Cu + BPC-157 + TB-500 |
| Molecular Weight | Combined MW: KPV (395.50 g/mol) + GHK-Cu (402.92 g/mol) + BPC-157 (1419.556 g/mol) + TB-500 (4,963.44 g/mol) |
| Amino Acid Count / Structure | Four-compound blend: three tripeptides/fragments + pentadecapeptide + Tβ4 fragment |
| PubChem CID | KPV: 53481987 | GHK-Cu: 16132295 | BPC-157: 108101 | TB-500: 16132341 |
| Sequence | See individual compound entries (SM-KPV, SM-GHK, SM-BPC157, SM-TB500) |
| Appearance | Co-lyophilized blue-tinted powder (due to GHK-Cu copper complex) |
| Storage | Store at -20°C. Protect from light. |
| Solubility | Soluble in sterile water and bacteriostatic water |
Compound Class & Mechanism
The four peptides in the KLOW blend have been characterized in preclinical research as engaging complementary pathway systems. KPV has been associated with NF-κB signaling modulation and PEPT1-mediated uptake in inflammatory pathway research. GHK-Cu has been associated with copper delivery and broad gene expression effects. BPC-157 has been associated with NO system modulation and matrix remodeling. TB-500 has been associated with actin dynamics and cellular migration.
The combination covers four distinct but functionally overlapping pathway systems — inflammation, matrix remodeling, angiogenesis, and cellular migration — in a single-preparation research format. For full characterization of each component, see the individual compound entries.
Research Findings
Research on this blend draws from the individual compound literatures. Published research has documented findings across the following combined research domains:
Key Research Areas
- Inflammatory Pathway Research: NF-κB and melanocortin pathway research via KPV
- Matrix Remodeling: copper-peptide and cytoprotective pathway research
- Vascular Research: combined angiogenic pathway research activity
- Multi-Pathway Research Designs: four-compound research preparations
Collectively, the KLOW research blend provides a single-preparation format for protocols requiring coverage of inflammatory, matrix, vascular, and cellular migration pathway research. See individual compound entries (KPV, GHK-Cu, BPC-157, TB-500) for full research characterization.
Research Context
Researchers study the KLOW blend as a convenient single-preparation format when research protocols call for co-administration of all four peptides. The blend is positioned as a multi-compound research tool covering inflammatory, matrix, and vascular research pathways in a single preparation.
References
Brzoska T. et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides. Endocrine Reviews.
Pickart L., Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences.
Sikiric P. et al. (2020). Brain-gut axis and the pentadecapeptide BPC-157. Current Pharmaceutical Design.
Goldstein AL. et al. (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine.
| REGULATORY & LEGAL NOTICE
Intended Use. This product is sold exclusively as a research chemical for use in controlled laboratory settings by qualified scientific professionals. It is intended solely for in vitro research, analytical standards, and non-clinical preclinical experimentation. The product is not a drug, dietary supplement, cosmetic, food product, or consumer article of any kind. Prohibited Uses. This product is NOT for use in humans, NOT for veterinary use, NOT for in vivo use in any species, NOT for diagnostic use, NOT for therapeutic use, NOT for food or agricultural use, and NOT for compounding into any preparation intended for administration to humans or animals. Qualified Professionals Only. Purchasers represent that they are qualified scientific professionals, licensed researchers, or authorized personnel at a research institution, and that this product will be handled in accordance with all applicable institutional, federal, state, and local regulations governing research chemicals. Regulatory Notice. The statements made regarding this product have not been evaluated by the U.S. Food and Drug Administration. This product has not been approved by the FDA for any therapeutic, diagnostic, or preventive use. Not a Compounding or Outsourcing Facility. Sirius Molecules is a research chemical supplier. Sirius Molecules is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Legal Compliance. Purchasers are solely responsible for ensuring that their acquisition, possession, handling, and use of this product complies with all applicable laws and regulations in their jurisdiction. |
